Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments

Autor: Bruera G, Ricevuto E

Publikováno v: Pharmacogenomics and Personalized Medicine, Vol Volume 13, Pp 601-617 (2020)

Gemma Bruera,1,2 Enrico Ricevuto1,2 On behalf of Oncology Network ASL1 Abruzzo1Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L’Aquila, L’Aquila, Italy; 2Department of Biotechnological and Applied C

Externí odkaz: https://doaj.org/article/912c412f1b9b49409e1472d26e412e96

Antioxidant capacity of polychaetes occurring at a natural CO2 vent system: Results of an in situ reciprocal transplant experiment

Autor: Ricevuto, E., Benedetti, M., Regoli, F., Spicer, J.I., Gambi, M.C.

Publikováno v: In Marine Environmental Research December 2015 112 Part A:44-51

A40 - Prevalence of KRAS, NRAS and BRAF mutations detected by massive parallel sequencing and differential clinical outcome in metastatic colorectal cancer (MCRC) patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy

Autor: Bruera, G., Pepe, F., Malapelle, U., Pisapia, P., Dal Mas, A., Di Giacomo, D., Calvisi, G., Troncone, G., Ricevuto, E.

Publikováno v: In Annals of Oncology October 2017 28 Supplement 6:vi14-vi14

Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme

Autor: De Giorgi, U, Carteni, G, Giannarelli, D, Basso, U, Galli, L, Cortesi, E, Caserta, C, Pignata, S, Sabbatini, R, Bearz, A, Buti, S, Lo Re, G, Berruti, A, Bracarda, S, Cognetti, F, Rastelli, F, Fornarini, G, Porta, C, Turci, D, Sternberg, Cn, Procopio, G, Falcone, A, Roila, F, Cascinu, S, Tirelli, U, Giustini, L, Sobrero, A, Cappuzzo, F, Tortora, G, Tassinari, D, Passalacqua, R, Pazzola, A, Surico, G, Maio, M, Benedetti, G, Barone, C, Adamo, V, Ricevuto, E, De Censi, A, Spada, M, Tonini, G, Pinto, C, Ciuffreda, L, Ruggeri, Em, Bengala, C, Scotti, V, Fagnani, D, Bonetti, A, Mitterer, M, Castiglione, F, Bidoli, P, Ferrau, F, Crino, L, Frassoldati, A, Marchetti, P, Mini, E, Scoppola, A, Verusio, C, Favaretto, A, Di Costanzo, F, Fasola, G, Merlano, M, Artioli, F, Di Leo, A, Romito, S, Maestri, A, Giorgio, Cg, Ionta, Mt, Verderame, F, Zampa, G, Numico, G, Minelli, M, Tagliaferri, P, Foa, P, Palmiotti, G, De Placido, S, Mattioli, R, Iuliano, F, Defraia, E, Siena, S, Clerico, M, Salvagno, L, Ceresoli, Gl, Bernardo, A, Di Lieto, M, Moroni, M, Maisano, M, Scartozzi, M, Scagliotti, G, Soraru, M, Pepe, S, Scaltriti, A, Gebbia, V, Testa, E, Lorusso, V, Bordonaro, R, De Signoribus, G, Tedde, N, Santoro, A, Francini, G, Aondio, G

Objective: To report the safety and efficacy results of patients enrolled in the Italian Nivolumab Renal Cell Cancer Expanded Access Programme. Patients and Methods: Patients with metastatic renal cell cancer (mRCC) previously treated with agents tar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cc1bee2a040cf0f99f4bf3071f70212
http://hdl.handle.net/2318/1693656

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.